| Issue |
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1171 - 1174 | |
| Section | Bioproduction | |
| DOI | https://doi.org/10.1051/medsci/2019232 | |
| Published online | 06 January 2020 | |
Exemples d’études de développabilité apportant un éclairage à la prise de décision
Developability assessment with case studies highlighting the decision taking
1 Biologics Research/Sanofi R&D, 13 quai Jules Guesde, 94403 Vitry-sur-Seine, France
2 Biologics Drug Products Development/Sanofi R&D, 13 quai Jules Guesde, 94403 Vitry-sur-seine, France
3
Integrated Drug Discovery Sanofi, 13 quai Jules Guesde, 94403 Vitry-sur-Seine, France
De nos jours, la génération d’anticorps thérapeutiques doit être plus rapide avec des coûts de développement moins importants. Pour cela, des prédictions in silico sont associées à des technologies de criblage et de caractérisation de pointe. Les exemples choisis ici sont non-exhaustifs mais illustrent ce besoin de travailler en parallèle.
Abstract
Therapeutic antibodies generation has to be faster with less development costs. This requires combination of in silico predictions associated with cutting edge screening and characterization technologies. Here, non-exhaustive examples illustrate this simultaneity need.
© 2019 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.